Abstract: The present disclosure describes methods of dosing vapendavir or a pharmaceutically acceptable salt thereof to treat subject in need thereof, thereby treating the respiratory enterovirus infection, wherein the respiratory enterovirus infection may be a respiratory enterovirus infection. The subject may further have an underlying condition, and the methods of the present disclosure may be useful in preventing or reducing acute exacerbations of the underlying condition in the subject. Pharmaceutical formulations of vapendavir are also disclosed.

Abstract: The present disclosure describes a method of treating a respiratory enterovirus infection in a human subject with COPD which includes administering to the subject a therapeutically effective amount of vapendavir or a pharmaceutically acceptable salt thereof, thereby treating the respiratory enterovirus infection in the subject. Pharmaceutical formulations of vapendavir are also disclosed.